PYX Resources: Achieving volume and diversification milestones. Watch the video here.
We're all being led to believe society has become very selfish and it's all about me, me, me these days. Well! my faith has been restored based on so many people spending so much time out of their busy lives to come on here and show so much concern over our investment in this company. WOW! how kind of you all to spend so much time worrying about others , especially people you don't know, and their misguided expenditure when you could be spending the time enjoying life with your beloved family and friends. Thank you..
Now enough is enough and I think we have all noted your concerns and it's time for you to go and enjoy your life, especially since most of us really don't know how long we might have left of it...
Again many thanks for your concerns...bye bye...
If the Agreement with Point Bio remains in place with adjustments to reflect the fact Lilly are now the new owners of Point then we have, in effect, a deal for PreCision with Lilly now...and Lilly, being who they are, I'm sure will be given access to our AVA6000 data if they express a serious interest in that too...
Anyone saying the PreCision platform has been overlooked yet again is misleading this BB...
Firstly, we already have a PreCision deal in place with Point Biopharma.
https://avacta.com/license-agreement-with-point-biopharma-inc/
Point Biopharma have just been acquired by Eli Lilly.
https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma
'Cryptophycin-52 (Cr-52, LY355703, 11) was designed by Eli Lilly, and its reported potency is 40- to 400-fold greater than that of paclitaxel or vinca alkaloids, making it a promising clinical candidate [111,112,113,114]. The mechanism of action involves suppressing microtubule dynamics and arresting cells in the G2/M phase. However, the co-crystallization data between Cr-52 and tubulin has not yet been solved, and the details of the binding site remain elusive. The Cr-52 structure is an analogue to cryptophycin-1, containing two hydroxy acids (units A and D) and two amino acids (units B and C). Due to the steric hindrance of the geminal dimethyl group, it is more resistant against ester hydrolysis than are cryptophycin-1 derivatives [103]. After numerous preclinical studies, Eli Lilly advanced Cr-52 to clinical trials, with aims to define the MTD, recommended dose, pattern of toxicity, and pharmacokinetic profile. Two Phase I clinical trials were performed, and a dose of 1.5 mg/m2 was recommended for Phase II evaluation on a day 1 and 8 schedule every 21 days [111].
Despite these findings, the treatment effect for NSCLC was not achieved as expected. Twenty-six patients were enrolled, of whom 25 were evaluable for toxicity and response. There were no responders when the weekly dose was lowered from 1.5 mg/m2 to 1.125 mg/m2. Median survival was 4.1 months, and toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation [113]. Another study was performed to determine the activity of LY355703 and to characterize its toxicity profile in patients with platinum-resistant advanced ovarian cancer, but only modest activity was observed in these patients [114].
Cr-52 failed in Phase II clinical studies due to the lack of efficacy and its high toxicity at the chosen doses. Although the cryptophycins were unable to advance to stand-alone agents, desirable characteristics including high potency, relative hydrophilicity, lack of P-gp susceptibility, and a common resistance mechanism make it an attractive ADC payload. '
Now who'se to say Lilly might not be looking at PreCision???
And from the placing announcement RNS...note last item...FURTHER EXPAND PIPELINE'..you was told...😉 question is...are they picking them out of the hat themselves or have they been approached by one or more companies to use their products...
'pre|CISION? pre-clinical pipeline:
o Next clinical candidate to be selected Q1 2025;
o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and
o Further expand pipeline;'
From the AVA6000 update...
'The continuing validation of the pre|CISION? platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION? to a range of warheads, including those much more potent than doxorubicin.'
Ice...they don't issue the TR1 Avacta does. A new investor only have to tell Avacta officially when they hold 3% then at every 1 % increase. Some companies choose to quietly forget...or delay notification if they are filling a large order for themselves and then speak out once the order is completed.
As soon as Avacta receives details of holding from the investor they notify the market with a TR1...now, if there is still a news blackout these might be held off or if an investor is currently buying more they too might be holding off.
We need to know who the European guys are...
'As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:
1. the adjustment factor will be (A+B)/(A+C), where:
1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild;
2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and
3. C = number of Shares comprised in the Bookbuild.
The principal remaining under the Bonds was reduced by a further £2.55 million to £38.25 million on 22 January 2024 following the fifth quarterly amortisation.'
25-Mar-24 16:32:47 50.44375 200,000 Sell* 50.50 51.00 100.89k
and a lot of sells just above the 50 mark...
I haven't sat and dne the maths but I wonder if our Bond friends will be getting their price reduced to the 50 mark...if so, then I'd say we're seeing some naughty forward selling...or a friendly sale to a mate at mates rates...
Almostrich...have you seen this from June 2025:
https://avacta.com/2015-06-11/